(CercleFinance.com) – The ongoing collaboration under the (PAN-TB) project to develop new treatments for tuberculosis has progressed with the signing of a joint development agreement (JDA) supporting the progress of two regimens tuberculosis (TB) combination treatment trials into phase 2 clinical development.
Partners will assess whether new treatment regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary tuberculosis using significantly shorter treatment times than existing treatment regimens.
The PAN-TB collaboration brings together philanthropic, non-profit and private sector organizations to accelerate the development of new, shorter treatment regimens to treat all forms of TB.
Five antimicrobial agents will be evaluated in this joint research, including Bedaquiline, a product of Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
